secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001493152-24-047145
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharma announces resignation of director Michael Jerman; replaces audit committee roles
--------------------------------------------------------------------------------

- On November 18, 2024, Michael Jerman resigned from the Board and as Chair of the Audit Committee, effective immediately, to pursue other activities, not due to a disagreement.
- On November 20, 2024, the Board appointed Dr. Matthew Del Giudice to the Audit Committee to fill the vacancy.
- The Board also appointed Matthew Pratt Whalen as Chairman of the Audit Committee.
- No exhibits other than the Fifth Refinancing Amendment (not attached here) were filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224047145/0001493152-24-047145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224047145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer